News und Analysen
DGAP-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
DGAP-Adhoc: Ad hoc: MorphoSys AG Reports Preliminary Q2 2022 Monjuvi U.S. Sales and Updates Financial Guidance for 2022
DGAP-News: Evotec, Boehringer Ingelheim, and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
DGAP-News: Evotec, Boehringer Ingelheim, and bioMérieux launch Aurobac, a joint venture to fight Antimicrobial Resistance
DGAP-News: Evotec completes acquisition of Rigenerand
DGAP-News: Evotec completes acquisition of Rigenerand
DGAP-News: Gerresheimer AG: Gerresheimer signs new credit facility in the amount of 150 million Euro
DGAP-News: Gerresheimer AG: Gerresheimer signs new credit facility in the amount of 150 million Euro
DGAP-News: Evotec SE reports results of Annual General Meeting 2022
DGAP-News: Evotec SE reports results of Annual General Meeting 2022
DGAP-News: MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
DGAP-News: MorphoSys and HIBio Enter Into Equity Participation and License Agreements for Felzartamab and MOR210
DGAP-News: Evotec enters a drug discovery collaboration with Janssen
DGAP-News: Evotec enters a drug discovery collaboration with Janssen
DGAP-News: Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47
DGAP-News: Pfizer, MorphoSys and Incyte Enter into Clinical Trial Collaboration for Monjuvi® (tafasitamab-cxix) in Combination with TTI-622, a Fusion Protein Directed Against CD47
Gerresheimer AG: Gerresheimer partners with MedTech start-up Adamant Health to revolutionize treatment of Parkinson’s disease
Gerresheimer AG: Gerresheimer partners with MedTech start-up Adamant Health to revolutionize treatment of Parkinson’s disease
DGAP-News: MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022
DGAP-News: MorphoSys Presents Multiple Analyses of the MANIFEST Phase 2 Trial Investigating the Potential of Pelabresib in the Treatment of Myelofibrosis at EHA 2022
DGAP-News: Gerresheimer AG: Annual General Meeting of Gerresheimer AG approves dividend of EUR 1.25 per share following a successful financial year – Gradual renewal of Supervisory Board initiated
DGAP-News: Gerresheimer AG: Annual General Meeting of Gerresheimer AG approves dividend of EUR 1.25 per share following a successful financial year – Gradual renewal of Supervisory Board initiated
DGAP-News: Evotec adds cell therapy manufacturing facility with acquisition of Rigenerand
DGAP-News: Evotec adds cell therapy manufacturing facility with acquisition of Rigenerand
DGAP-News: Evotec and Almirall enter into a multi-target alliance in medical dermatology
DGAP-News: Evotec and Almirall enter into a multi-target alliance in medical dermatology
DGAP-News: MorphoSys AG Reports Outcome of Annual General Meeting 2022
DGAP-News: MorphoSys AG Reports Outcome of Annual General Meeting 2022
DGAP-News: Evotec and Sernova announce exclusive strategic partnership for iPSC-based beta cell replacement therapy to advance a 'functional cure' for diabetes
DGAP-News: Evotec and Sernova announce exclusive strategic partnership for iPSC-based beta cell replacement therapy to advance a 'functional cure' for diabetes
DGAP-News: Gerresheimer AG: Gerresheimer executes on its growth strategy in Emerging Markets boosting capacities in India
DGAP-News: Gerresheimer AG: Gerresheimer executes on its growth strategy in Emerging Markets boosting capacities in India
DGAP-News: MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings
DGAP-News: MorphoSys to Present New Data on Pelabresib and Monjuvi® (tafasitamab-cxix) at the 2022 European Hematology Association (EHA) and American Society of Clinical Oncology (ASCO) Annual Meetings
DGAP-News: RHÖN-KLINIKUM Aktiengesellschaft: Financial year 2022 again marked by COVID-19 pandemic
DGAP-News: RHÖN-KLINIKUM Aktiengesellschaft: Financial year 2022 again marked by COVID-19 pandemic
DGAP-News: Evotec SE reports results for the first quarter 2022 and provides corporate update
DGAP-News: Evotec SE reports results for the first quarter 2022 and provides corporate update
DGAP-News: Evotec and Bristol Myers Squibb extend and expand strategic partnership in protein degradation
DGAP-News: Evotec and Bristol Myers Squibb extend and expand strategic partnership in protein degradation
Gerresheimer AG: Gerresheimer and Portal enter strategic partnership to treat chronically ill patients with innovative needle-free drug-delivery solution
Gerresheimer AG: Gerresheimer and Portal enter strategic partnership to treat chronically ill patients with innovative needle-free drug-delivery solution
DGAP-Adhoc: RHÖN-KLINIKUM Aktiengesellschaft: The Board of Management of RHÖN-KLINIKUM AG considers timely agreement with the State of Hesse on granting subsidies to UKGM to be questionable
DGAP-Adhoc: RHÖN-KLINIKUM Aktiengesellschaft: The Board of Management of RHÖN-KLINIKUM AG considers timely agreement with the State of Hesse on granting subsidies to UKGM to be questionable
DGAP-News: MorphoSys AG Reports First Quarter 2022 Financial Results
DGAP-News: MorphoSys AG Reports First Quarter 2022 Financial Results
DGAP-News: Evotec SE to announce results for the first quarter 2022 on 11 May 2022
DGAP-News: Evotec SE to announce results for the first quarter 2022 on 11 May 2022
DGAP-News: Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022
DGAP-News: Invitation to MorphoSys' First Quarter 2022 Financial Results Conference Call on May 5, 2022